Point-of-Care Xpert MTB/RIF Testing Feasible in Primary Care

Faster TB test fails to improve prognosis
28th October 2013
Sputum Test May not Hold Key to TB Eradication
29th October 2013
Faster TB test fails to improve prognosis
28th October 2013
Sputum Test May not Hold Key to TB Eradication
29th October 2013

Point-of-Care Xpert MTB/RIF Testing Feasible in Primary Care

Point-of-care Xpert MTB/RIF tuberculosis testing is associated with more patients getting same-day diagnosis and having same-day treatment initiation but does not result in improved tuberculosis-related morbidity, according to a study published online Oct. 28 in The Lancet.

Grant Theron, Ph.D., from the University of Cape Town in South Africa, and colleagues conducted a multicenter, randomized trial to examine the feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing at primary care health care facilities in southern Africa. A total of 758 patients were randomized to receive smear microscopy, and 744 to nurse-performed Xpert MTB/RIF.

The researchers found that there were 182 culture positive patients in the smear microscopy group and 185 culture positive patients in the Xpert MTB/RIF group. At two and six months there were no significant differences between the groups in tuberculosis-related morbidity in culture-positive patients (as measured by TBscore and Karnofsky performance score). Compared with microscopy, sensitivity was higher and specificity similar with point-of-care MTB/RIF. Sensitivity was similar and specificity higher for point-of-care MTB/RIF versus laboratory-based MTB/RIF. More patients in the MTB/RIF group had a same-day diagnosis, same-day treatment initiation, and more culture-positive patients were on treatment by the end of the study, due to reduced dropout.

“The benefits did not translate into lower tuberculosis-related morbidity, partly because of high levels of empirical-evidence-based treatment in smear-negative patients,” the authors write.

Read more Doctors Lounge, 28 October 2013